EGFR 突变晚期 NSCLC 新突破：Izalontamab Brengitecan 优于含铂化疗
Posted inClinical Updates Oncology Respiratory

Izalontamab Brengitecan Shows Promising Efficacy Over Platinum Chemotherapy in EGFR-Mutated NSCLC Post-Third-Generation EGFR TKI Progression

The PANKU-Lung01 phase 3 trial demonstrates izalontamab brengitecan significantly extends progression-free survival compared to platinum-based chemotherapy in EGFR-mutated advanced non-squamous NSCLC after failure of third-generation EGFR TKIs, with manageable safety profile.